ATNF Stock Price History and Quote Analysis: Insights for Investors
180 Life Sciences Corp.
Stock Price Today
180 Life Sciences Corp. (ATNF) stock declined over -3.19%, trading at $1.82 on NASDAQ, down from the previous close of $1.88. The stock opened at $1.89, fluctuating between $1.77 and $1.93 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Company Information
| Employees | 4 |
| Beta | 0.449 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
180 Life Sciences Corp. (NASDAQ: ATNF) stock price is $1.82 in the last trading session. During the trading session, ATNF stock reached the peak price of $1.93 while $1.77 was the lowest point it dropped to. The percentage change in ATNF stock occurred in the recent session was -3.19% while the dollar amount for the price change in ATNF stock was -$0.06.
The NASDAQ listed ATNF is part of Biotechnology industry that operates in the broader Healthcare sector. 180 Life Sciences Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Raphael Mechoulam Ph.D.
Co-Founder & Member of Scientific Advisory Board
Mr. Jason Assad
Director of IR
Dr. James N. Woody M.D., Ph.D.
Chief Executive Officer & Director
Dr. Jonathan B. Rothbard Ph.D.
Chief Scientific Officer
Prof. Jagdeep Nanchahal
Chief Medical Officer & Chairman of Clinical Advisory Board
Sir Marc Feldmann Ph.D.
Co-Founder & Executive Co-Chairman
Mr. Ozan Pamir C.F.A.
Chief Financial Officer & Sec.
ATNF's closing price is 38.93% higher than its 52-week low of $1.31 where as its distance from 52-week high of $15.71 is -88.42%.
Number of ATNF employees currently stands at 4.
Official Website of ATNF is: https://180lifesciences.com
ATNF could be contacted at phone 650 507 0669 and can also be accessed through its website. ATNF operates from Building 4, Palo Alto, CA 94306, United States.
ATNF stock volume for the day was 56.08K shares. The average number of ATNF shares traded daily for last 3 months was 599.6K.
The market value of ATNF currently stands at $1.76M with its latest stock price at $1.82 and 969.6K of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com